Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
Everolimus is an oral mTOR inhibitor with demonstrated preliminary efficacy and safety in
diffuse large B-cell lymphoma (DLBCL) in both preclinical and clinical studies. The purpose
of this research study is to determine whether Everolimus plus rituximab is safe and
effective in participants with relapsed or refractory DLBCL. Everolimus is an investigational
drug that works by blocking a special protein that helps cancer cells grow. The safety and
effectiveness of Everolimus in the treatment of DLBCL has not yet been fully determined and
is still investigational. The other drug in this study, rituximab, is approved by the US Food
and Drug Administration (FDA) for use in patients who have diffuse large B-cell lymphoma and
certain other types of non-Hodgkin lymphoma. Rituximab is a drug that destroys both normal
and cancerous B-cells.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Beth Israel Deaconess Medical Center Dana-Farber Cancer Institute Novartis